What Is Bioavailability? Why Supplement Form Matters
Bioavailability is the fraction of a dose that reaches circulation unchanged. Why it decides whether a correct dose does anything, and where the claims overreach.
The Short Answer
Bioavailability is the fraction of an administered dose that reaches systemic circulation in unchanged form, conventionally written as F and expressed as a percentage. An intravenous dose is one hundred percent by definition, and everything taken orally is less, because a substance must survive the stomach, cross the intestinal wall, and pass through the liver before it enters general circulation. It is measured from the area under the plasma concentration-time curve, and it determines whether a label dose has any relationship to what the body actually receives: a 500 mg dose at five percent bioavailability delivers less than a 50 mg dose at sixty percent, which is why form and formulation frequently matter more than the number printed on the bottle.
The Four Barriers
Anything swallowed faces four sequential losses, and a formulation can only address the ones it is designed for.
Dissolution. A compound must dissolve in gastrointestinal fluid before it can be absorbed. Poorly water-soluble compounds, which includes most polyphenols and fat-soluble vitamins, are limited here first, and particle size reduction, amorphous forms and lipid carriers all address this specific step.
Stability. Gastric acid and digestive enzymes degrade some compounds before absorption. Enteric coating exists for this, and probiotics, some enzymes and certain peptides depend on it.
Intestinal absorption. Crossing the enterocyte requires either passive diffusion, which favours moderately lipophilic small molecules, or a transporter. Transporter-dependent absorption saturates, which is why some nutrients show falling percentage absorption as dose rises. Efflux transporters, principally P-glycoprotein, actively pump some compounds back into the lumen.
First-pass metabolism. Blood from the intestine goes to the liver before general circulation, and the liver metabolises a large fraction of many compounds on that first pass. Intestinal enzymes contribute too. This is the largest single loss for many polyphenols, and it is why a compound can be well absorbed and still have low bioavailability.
Where Form Genuinely Changes the Answer
Some form differences are large and well documented. These are the cases where the choice is worth making deliberately.
- Curcumin. Unformulated curcumin has bioavailability low enough that plasma concentrations after a gram-level dose are often near the limit of detection. Phospholipid complexes, piperine co-administration, nanoparticle and micellar formulations raise exposure substantially, in some comparisons by an order of magnitude or more. This is the clearest case in the supplement world.
- Magnesium. Oxide is poorly absorbed and has a laxative effect that reflects it. Citrate, glycinate, malate and threonate are better absorbed, and the differences among those are smaller than the difference from oxide.
- Iron. Heme iron is absorbed more efficiently than non-heme, absorption is regulated by body stores through hepcidin, and vitamin C co-administration increases non-heme absorption while calcium, tannins and phytates reduce it. Alternate-day dosing improves fractional absorption compared with daily dosing, which is a genuinely useful and underused finding.
- Coenzyme Q10. Ubiquinol and solubilised ubiquinone formulations achieve higher plasma concentrations than plain powdered ubiquinone, and it should be taken with fat.
- Fat-soluble vitamins. A, D, E and K all require dietary fat for absorption, and taking them on an empty stomach substantially reduces uptake. This is a free improvement that costs nothing but timing.
- Folate and B12. Methylated and other reduced forms bypass conversion steps that are limited in some individuals, which is a real consideration for a minority rather than a general upgrade.
Where the Claims Overreach
Enhanced bioavailability is also the most heavily marketed property in the supplement industry, and several patterns should raise scepticism.
Bioavailability against outcome. Higher plasma concentration is a means, not an end. A formulation demonstrating a fivefold increase in plasma exposure has demonstrated exactly that, and whether the clinical effect scales with exposure is a separate question that is usually not tested. For some compounds the metabolites, not the parent molecule, carry the activity, which makes parent-compound plasma levels a poor proxy.
Liposomal claims. Genuine liposomal encapsulation is a specific physical structure. Many products labelled liposomal are lipid mixtures without verified encapsulation, and independent characterisation is rare. Where third-party pharmacokinetic data exist for a specific product, the claim is assessable; where they do not, the word is decoration.
The wrong-compound problem. Enhanced delivery is worth paying for when low bioavailability is the limiting factor. Vitamin C at moderate doses, magnesium citrate and most B vitamins are already absorbed adequately, so a premium delivery system addresses a constraint that was not binding.
Comparison against the worst option. A formulation compared against unformulated curcumin or magnesium oxide will look impressive. Compared against the reasonable alternative, the margin is usually much smaller, and the comparator choice is where most of the marketing effect lives.
The Free Improvements
Before paying for a formulation, several adjustments cost nothing and are frequently larger than the formulation difference.
Take fat-soluble compounds with fat. Vitamins A, D, E and K, CoQ10, curcumin, astaxanthin and lutein all benefit, and the meal does not need to be large.
Split doses where absorption saturates. Calcium above roughly 500 mg per dose, magnesium at higher intakes and vitamin C above about 200 mg per dose all show falling fractional absorption. Two smaller doses deliver more than one large one.
Separate the antagonists. Calcium reduces iron and zinc absorption; iron and zinc compete with each other; calcium and magnesium compete at high doses; and coffee and tea tannins reduce non-heme iron absorption substantially. Four hours of separation resolves most of these.
Respect timing constraints. Iron on an empty stomach with vitamin C where tolerated. Thyroid medication four hours from calcium, iron and magnesium. Probiotics as their product directs, since strain survival differs.
The general point: absorption is a property of the dose in context, not of the molecule. The same tablet taken with a fatty meal and taken with coffee on an empty stomach are two different interventions.
How to Read a Bioavailability Claim
Five questions separate a substantiated claim from a decorated one.
Compared with what? Against the unformulated worst case, or against the sensible standard alternative.
Measured how? Area under the curve in humans is the standard. Cell culture uptake, animal data or a single time-point plasma measurement are all weaker, and a maximum concentration without an area under the curve can reflect faster absorption rather than more of it.
In whom? Small crossover studies in young healthy volunteers, often industry-funded, are the norm. That is acceptable evidence for a pharmacokinetic claim and does not extend to a clinical one.
Does the product match the studied material? Branded extracts with published pharmacokinetics are identifiable by name. A product citing that literature while using a different material is citing someone else's data.
Does the outcome evidence use the same form? This is the question that matters most and is asked least. If the clinical trials used unformulated material and the product is an enhanced formulation, the dose relationship is unknown, and higher exposure is not automatically better.
The AEONNN Perspective
Bioavailability is the reason AEONNN's Stack Builder distinguishes an Element from a product. An Element names what should be raised and why; the form, the dose and the timing are what determine whether that happens. Two products carrying the same ingredient name can differ by an order of magnitude in delivered exposure, which makes the ingredient name insufficient as a recommendation.
The Pharmacokinetics layer of the Database Matrix, drawing on HMDB and PubChem, is where absorption, metabolism and half-life data enter the reasoning, and the Quality layer is where formulation and third-party verification enter. Apothecary sits on top of both: when a member moves from an Element to a specific commercial product, form and verified formulation are among the criteria it evaluates independently.
Timing counts as part of the recommendation rather than as an optional refinement, because it frequently outweighs the formulation choice. A fat-soluble compound taken without fat, or an iron dose taken with coffee, has already given up more than most premium delivery systems recover.
Pillar Matrix mapping
Metabolic and Cardiovascular Health, Cellular Energy and Repair
Database Matrix layers
- Pharmacokinetics Layer (HMDB, PubChem)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Mechanistic Layer (KEGG, Reactome, UniProt)
Frequently Asked
What is bioavailability in simple terms?
The share of a dose that actually reaches your bloodstream unchanged. An intravenous dose is one hundred percent by definition; anything swallowed is less, because it has to survive the stomach, cross the gut wall and pass through the liver first.
Why does supplement form matter?
Because bioavailability can differ by an order of magnitude between forms of the same compound. A 500 mg dose at five percent bioavailability delivers less than a 50 mg dose at sixty percent, so form can matter more than the number on the label.
What is first-pass metabolism?
Blood leaving the intestine passes through the liver before entering general circulation, and the liver metabolises a large fraction of many compounds on that first pass. It is why a substance can be well absorbed from the gut and still have low bioavailability.
Which supplements have poor bioavailability?
Unformulated curcumin is the standard example, with plasma levels often near the limit of detection after gram-level doses. Magnesium oxide, non-heme iron, resveratrol, plain powdered CoQ10 and most polyphenols are also strongly limited.
Are liposomal supplements worth it?
Sometimes, and the word alone is not evidence. Genuine liposomal encapsulation is a specific physical structure, many products labelled liposomal are lipid mixtures without verified encapsulation, and the question is whether third-party pharmacokinetic data exist for that specific product.
How can I improve absorption without buying special formulations?
Take fat-soluble compounds with a meal containing fat, split doses where absorption saturates such as calcium above 500 mg, separate competing minerals by four hours, and keep coffee and tea away from non-heme iron doses. These changes are free and often larger than a formulation upgrade.
Does higher bioavailability mean better results?
Not automatically. Higher plasma exposure is a means rather than an end, the clinical effect does not necessarily scale with it, and for some compounds the active agents are metabolites rather than the parent molecule. It also matters whether the outcome trials used the same form.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.